Bronconex Acticap

Kraj: Nowa Zelandia

Język: angielski

Źródło: Medsafe (Medicines Safety Authority)

Składnik aktywny:

Mometasone furoate 400ug (anhydrous)

Dostępny od:

Organon (New Zealand) Limited

INN (International Nazwa):

Mometasone furoate 400 µg (anhydrous)

Dawkowanie:

400 mcg/dose

Forma farmaceutyczna:

Powder for inhalation

Skład:

Active: Mometasone furoate 400ug (anhydrous) Excipient: Lactose

Sztuk w opakowaniu:

Inhaler, metered, DPI, (sample), 14 dose units

Klasa:

Prescription

Typ recepty:

Prescription

Wyprodukowano przez:

MSD International GmbH (Singapore Branch)

Wskazania:

Bronconex Acticap is indicated for prophylactic therapy in the management of patients with asthma of all severities, including patients who have been dependent upon either inhaled or systemically administered corticosteroids and non-corticosteroid-dependent patients inadequately controlled on other drug regimens.

Podsumowanie produktu:

Package - Contents - Shelf Life: Inhaler, metered, DPI, (sample) - 14 dose units - 18 months from date of manufacture stored at or below 25°C - Inhaler, metered, DPI - 30 dose units - 18 months from date of manufacture stored at or below 25°C - Inhaler, metered, DPI - 60 dose units - 18 months from date of manufacture stored at or below 25°C

Data autoryzacji:

2000-12-05